Clinical Trials
28 trialsCAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Zhujiang Hospital
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
Institute of Hematology & Blood Diseases Hospital, China
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
Kecellitics Biotech Company Ltd
Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies
Sichuan University
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
iCell Gene Therapeutics
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
iCell Gene Therapeutics
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
Taiga Biotechnologies, Inc.
ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
Hrain Biotechnology Co., Ltd.
Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
ToTem
University College, London
Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT
Shenzhen Second People's Hospital
Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia
Guangdong Provincial People's Hospital
Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
ATAC-AML-01
Maisonneuve-Rosemont Hospital
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
Affiliated Hospital to Academy of Military Medical Sciences
CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Synta Pharmaceuticals Corp.
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors
National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer
National Cancer Institute (NCI)
NHL
Cambridge Antibody Technology
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Cambridge Antibody Technology
Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease
Cambridge Antibody Technology